Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Do biomarker changes during neoadjuvant endocrine therapy reflect breast tumor receptor status?

Your institute does not have access to this article

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

References

  1. Early Breast Cancer Trialists' Collaborative Group. (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365: 1687–1717

  2. Baum M et al. (2002) Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359: 2131–2139

    CAS  Article  Google Scholar 

  3. Ellis M et al. (2001) Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ERB-1 and/or Erb-2 positive, estrogen receptor-positive primary breast cancer: evidence from a Phase III randomized trial. J Clin Oncol 19: 3808–3816

    CAS  Article  Google Scholar 

  4. Osborne CK et al. (2005) Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer. Clin Cancer Res 11(Pt 2): 865s–870s

    Google Scholar 

Download references

Acknowledgements

The synopsis was written by Petra Roberts, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

Authors

Ethics declarations

Competing interests

Dr Dickler participates in an AstraZeneca Speakers' Bureau.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Dickler, M. Do biomarker changes during neoadjuvant endocrine therapy reflect breast tumor receptor status?. Nat Rev Clin Oncol 2, 498–499 (2005). https://doi.org/10.1038/ncponc0298

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncponc0298

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing